This paragraph from the RLS-UK paper to the All Party Parliamentary Group stood out :
"Research by the London School of Economics as part of The European Brain Council’s ‘Value of Treatment' white paper identified that the societal annual cost of RLS to be second only to dementia and above conditions such as stroke, Parkinson’s disease, multiple sclerosis and epilepsy."
It went on to say that "Specific analysis of cases showed that significant cost savings could be made by tackling inadequacies in the current management pathway and treatment of RLS"